Romeo, M.; Di Nardo, F.; Napolitano, C.; Basile, C.; Palma, C.; Vaia, P.; Dallio, M.; Federico, A.
Exploring the Epidemiologic Burden, Pathogenetic Features, and Clinical Outcomes of Primary Liver Cancer in Patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Scoping Review. Diabetology 2025, 6, 79.
https://doi.org/10.3390/diabetology6080079
AMA Style
Romeo M, Di Nardo F, Napolitano C, Basile C, Palma C, Vaia P, Dallio M, Federico A.
Exploring the Epidemiologic Burden, Pathogenetic Features, and Clinical Outcomes of Primary Liver Cancer in Patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Scoping Review. Diabetology. 2025; 6(8):79.
https://doi.org/10.3390/diabetology6080079
Chicago/Turabian Style
Romeo, Mario, Fiammetta Di Nardo, Carmine Napolitano, Claudio Basile, Carlo Palma, Paolo Vaia, Marcello Dallio, and Alessandro Federico.
2025. "Exploring the Epidemiologic Burden, Pathogenetic Features, and Clinical Outcomes of Primary Liver Cancer in Patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Scoping Review" Diabetology 6, no. 8: 79.
https://doi.org/10.3390/diabetology6080079
APA Style
Romeo, M., Di Nardo, F., Napolitano, C., Basile, C., Palma, C., Vaia, P., Dallio, M., & Federico, A.
(2025). Exploring the Epidemiologic Burden, Pathogenetic Features, and Clinical Outcomes of Primary Liver Cancer in Patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Scoping Review. Diabetology, 6(8), 79.
https://doi.org/10.3390/diabetology6080079